Intranasal delivery of an adenovirus-vector vaccine co-expressing a modified spike protein and a genetic adjuvant confers lasting mucosal immunity against SARS-CoV-2.

Antiviral Res · 2023 · PMC10265935 · PMID 37327877

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Furthermore, S-specific IFN-γ-producing T cells in the lungs remained detectable 1 year after vaccination, though this finding did not reach statistical significance ( Fig. 4 E).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.